Talaporfin

Drug Profile

Talaporfin

Alternative Names: Aptocine; Laserphyrin; Leserfin; Litx; LS 11; ME 2906; Mono-L-aspartyl chlorin e6; NP e6; NPE 6; Taporfin sodium

Latest Information Update: 06 May 2015

Price : $50

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Light Sciences Oncology; Meiji Seika Pharma; The Childrens Hospital of Philadelphia
  • Class Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glioma; Lung cancer
  • Preregistration Oesophageal cancer
  • Phase II Benign prostatic hyperplasia
  • No development reported Cardiovascular disorders; Colorectal cancer; Hepatocellular carcinoma; Prostate cancer
  • Discontinued Age-related macular degeneration; Neurofibromatoses

Most Recent Events

  • 06 May 2015 No recent reports on development identified - Phase-I/II for Hepatocellular carcinoma in Taiwan (IV)
  • 06 May 2015 No recent reports on development identified - Phase-III for Colorectal cancer (Metastatic disease) in USA, Bosnia-Herzegovina, Austria, Croatia, Germany, India, Italy, Latvia, Poland, Romania, Russia, Serbia and Montenegro, Sweden and Ukraine (IV)
  • 06 May 2015 No recent reports on development identified - Phase-III for Hepatocellular carcinoma in USA, Australia, China, Croatia, India, Italy, Hong Kong, Philippines, Poland, Malaysia, Serbia, Singapore, South Korea, Sweden and Thailand (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top